Literature DB >> 16407771

Distribution of AAV2-hAADC-transduced cells after 3 years in Parkinsonian monkeys.

Marcel M Daadi1, Phillip Pivirotto, John Bringas, Janet Cunningham, John Forsayeth, Jamie Eberling, Krys S Bankiewicz.   

Abstract

The present report describes for the first time, the stability of recombinant adeno-associated virus serotype 2 (AAV2) human aromatic L-amino acid decarboxylase (hAADC) gene transfer after 3-year survival time in a non-human primate model of Parkinson's disease. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned monkeys were treated with six injections of 30 microl/site of AAV2-hAADC at a concentration of 2 x 10(12) vg/ml into the caudate and putamen. Stereological analysis revealed a 46.6% increase in the total number of AAV2-hAADC-transduced cells in the striatum between 8 weeks and 3 years after gene transfer survival time. In the 8-week animals, the distribution of the AADC+ cells was dispersed and heterogeneous, whereas in the 3-year animals it was widespread and homogenous. Confocal analysis demonstrated that approximately 85% of the AADC+ cells were neuronal nuclei immunoreactive.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16407771     DOI: 10.1097/01.wnr.0000198952.38563.05

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  17 in total

1.  Striatal readministration of rAAV vectors reveals an immune response against AAV2 capsids that can be circumvented.

Authors:  Carmen S Peden; Fredric P Manfredsson; Sharon K Reimsnider; Amy E Poirier; Corinna Burger; Nicholas Muzyczka; Ronald J Mandel
Journal:  Mol Ther       Date:  2009-01-13       Impact factor: 11.454

2.  Safety and tolerability of magnetic resonance imaging-guided convection-enhanced delivery of AAV2-hAADC with a novel delivery platform in nonhuman primate striatum.

Authors:  Waldy San Sebastian; R Mark Richardson; Adrian P Kells; Clementine Lamarre; John Bringas; Philip Pivirotto; Ernesto A Salegio; Stephen J Dearmond; John Forsayeth; Krystof S Bankiewicz
Journal:  Hum Gene Ther       Date:  2012-01-26       Impact factor: 5.695

3.  Novel platform for MRI-guided convection-enhanced delivery of therapeutics: preclinical validation in nonhuman primate brain.

Authors:  R Mark Richardson; Adrian P Kells; Alastair J Martin; Paul S Larson; Philip A Starr; Peter G Piferi; Geoffrey Bates; Lisa Tansey; Kathryn H Rosenbluth; John R Bringas; Mitchel S Berger; Krystof S Bankiewicz
Journal:  Stereotact Funct Neurosurg       Date:  2011-04-14       Impact factor: 1.875

4.  Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease.

Authors:  R Mark Richardson; Adrian P Kells; Kathryn H Rosenbluth; Ernesto Aguilar Salegio; Massimo S Fiandaca; Paul S Larson; Philip A Starr; Alastair J Martin; Russell R Lonser; Howard J Federoff; John R Forsayeth; Krystof S Bankiewicz
Journal:  Mol Ther       Date:  2011-02-22       Impact factor: 11.454

5.  Biodistribution and safety assessment of AAV2-GAD following intrasubthalamic injection in the rat.

Authors:  Helen L Fitzsimons; Veronique Riban; Ross J Bland; Jennifer L Wendelken; Christine V Sapan; Matthew J During
Journal:  J Gene Med       Date:  2010-04       Impact factor: 4.565

6.  Acrolein-mediated alpha-synuclein pathology involvement in the early post-injury pathogenesis of mild blast-induced Parkinsonian neurodegeneration.

Authors:  Glen Acosta; Nicholas Race; Seth Herr; Joseph Fernandez; Jonathan Tang; Edmond Rogers; Riyi Shi
Journal:  Mol Cell Neurosci       Date:  2019-06-12       Impact factor: 4.314

7.  Magnetic resonance imaging-guided delivery of adeno-associated virus type 2 to the primate brain for the treatment of lysosomal storage disorders.

Authors:  E Aguilar Salegio; A P Kells; R M Richardson; P Hadaczek; J Forsayeth; J Bringas; S P Sardi; M A Passini; L S Shihabuddin; S H Cheng; M S Fiandaca; K S Bankiewicz
Journal:  Hum Gene Ther       Date:  2010-09       Impact factor: 5.695

Review 8.  Gene therapy in Parkinson's disease: rationale and current status.

Authors:  Li Rebekah Feng; Kathleen A Maguire-Zeiss
Journal:  CNS Drugs       Date:  2010-03       Impact factor: 5.749

Review 9.  Non-human primate models of PD to test novel therapies.

Authors:  Marc Morissette; Thérèse Di Paolo
Journal:  J Neural Transm (Vienna)       Date:  2017-04-08       Impact factor: 3.575

10.  Detection, purification and identification of an endogenous inhibitor of L-Dopa decarboxylase activity from human placenta.

Authors:  Alice-Georgia Vassiliou; Emmanuel G Fragoulis; Dido Vassilacopoulou
Journal:  Neurochem Res       Date:  2008-11-13       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.